Adherence to biologics in patients with psoriasis

References

• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 [cited 2017 Nov 3];41(3 Pt 1):401–407. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10459113
   PubMed Web of Science ®Google Scholar
• Augustin M, Holland B, Dartsch D, et al. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222(4):363–374.
   PubMed Web of Science ®Google Scholar
• Thorneloe RJ, Bundy C, Griffiths CEM, et al. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31.
   PubMed Web of Science ®Google Scholar
• Fathi R, Armstrong AW. The role of biologic therapies in dermatology. Med Clin North Am. 2015;99(6):1183–1194.
   PubMed Web of Science ®Google Scholar
• Raval K, Lofland JH, Waters H, et al. Disease and treatment burden of psoriasis: examining the impact of biologics. J Drugs Dermatol. 2011 [cited Sep 26];10(2):189–196. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/21283925
   PubMed Web of Science ®Google Scholar
• Chan SA, Hussain F, Lawson LG, et al. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat. 2013;24(1):64–69.
   PubMed Web of Science ®Google Scholar
• Bhosle MJ, Feldman SR, Camacho FT, et al. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis. J Dermatolog Treat. 2006;17(5):294–301.
   PubMed Web of Science ®Google Scholar
• Di Lernia V, Tasin L, Pellicano R, et al. Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis. J Dermatolog Treat. 2012;23(6):404–409.
   PubMed Web of Science ®Google Scholar
• Menting SP, Sitaram AS, Bonnerjee-van der Stok HM, et al. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol. 2014;171(4):875–883.
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, Zweegers J, Kievit W, et al. “Happy” drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network. Br J Dermatol. 2014;171(5):1189–1196.
   PubMed Web of Science ®Google Scholar
• Brunasso AMG, Puntoni M, Massone C. Drug survival rates of biologic treatments in patients with psoriasis vulgaris. Br J Dermatol. 2012;166(2):447–449.
   PubMed Web of Science ®Google Scholar
• Yeung H, Wan J, van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(1):64–72.
   PubMed Web of Science ®Google Scholar
• Goren A, Carter C, Lee S. Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis. J Dermatolog Treat. 2016;27(1):43–50.
   PubMed Web of Science ®Google Scholar
• Sandoval LF, Huang KE, Feldman SR. Adherence to ustekinumab in psoriasis patients. J Drugs Dermatol. 2013 [cited Mar 16];12(10):1090–1092. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/24085042
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201–209.
   PubMedGoogle Scholar
• Hsu DY, Gniadecki R. Patient adherence to biologic agents in psoriasis. Dermatology. 2016;232(3):326–333.
   PubMed Web of Science ®Google Scholar
• West C, Narahari S, O’Neill J, et al. Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol Online J. 2013 [cited Jan 24];19(5):18182. Available from:: http://www.ncbi.nlm.nih.gov/pubmed/24011280
   PubMedGoogle Scholar
• Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057–1065.e4.
   PubMed Web of Science ®Google Scholar
• Marinas JE, Kim WB, Shahbaz A, et al. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: a Canadian multicentre retrospective study. Australas J Dermatol. 2016 Nov.
   PubMedGoogle Scholar
• Ross C, Marshman G, Grillo M, et al. Biological therapies for psoriasis: adherence and outcome analysis from a clinical perspective. Australas J Dermatol. 2016;57(2):137–140.
   PubMed Web of Science ®Google Scholar
• Umezawa Y, Nobeyama Y, Hayashi M, et al. Drug survival rates in patients with psoriasis after treatment with biologics. J Dermatol. 2013;40(12):1008–1013.
   PubMed Web of Science ®Google Scholar
• Davila-Seijo P, Dauden E, Carretero G, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016;30(11):1942–1950.
   PubMed Web of Science ®Google Scholar
• Inzinger M, Wippel-Slupetzky K, Weger W, et al. Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily life conditions: report from the Psoriasis Registry Austria. Acta Derm Venereol. 2016;96(2):207–212.
   PubMed Web of Science ®Google Scholar
• Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135(11):2632–2640.
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, van Lumig PPM, Driessen RJB, et al. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis. Br J Dermatol. 2014;170(2):415–424.
   PubMed Web of Science ®Google Scholar
• Clemmensen A, Spon M, Skov L, et al. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatology Venereol. 2011;25(9):1037–1040.
   PubMed Web of Science ®Google Scholar
• Vilarrasa E, Notario J, Bordas X, et al. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol. 2016;74(6):1066–1072.
   PubMed Web of Science ®Google Scholar
• Jacobi A, Rustenbach SJ, Augustin M. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. Int J Dermatol. 2016;55(3):296–302.
   PubMed Web of Science ®Google Scholar
• Shalom G, Cohen AD, Ziv M, et al. Biologic drug survival in Israeli psoriasis patients. J Am Acad Dermatol. 2017;76(4):662–669.e1.
   PubMed Web of Science ®Google Scholar
• van den Reek JMPA, Tummers M, Zweegers J, et al. Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry. J Eur Acad Dermatol Venereol. 2015;29(3):560–565.
   PubMed Web of Science ®Google Scholar
• Spertino J, Lopez-Ferrer A, Vilarrasa E, et al., Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions. J Eur Acad Dermatol Venereol. 2014 [cited Sep 28];28(11):1514–1521. http://www.ncbi.nlm.nih.gov/pubmed/25493314
   PubMed Web of Science ®Google Scholar
• López-Ferrer A, Vilarrasa E, Gich IJ, et al. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol. 2013;169(5):1141–1147.
   PubMed Web of Science ®Google Scholar
• Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology. 2015;230(1):46–54.
   PubMed Web of Science ®Google Scholar
• Zweegers J, van den Reek JMPA, van de Kerkhof PCM, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t. Br J Dermatol. 2016;175(2):340–347.
   PubMed Web of Science ®Google Scholar
• Esposito M, Gisondi P, Cassano N, et al. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3):666–672.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164(5):1091–1096.
   PubMed Web of Science ®Google Scholar
• Gniadecki R, Bang B, Bryld LE, et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–252.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhou H, Cai B, et al. Group-based trajectory modeling to assess adherence to biologics among patients with psoriasis. Clinicoecon Outcomes Res. 2014;6:197–208.
   PubMedGoogle Scholar
• Zschocke I, Ortland C, Reich K. Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician-patient interaction and communication. J Eur Acad Dermatol Venereol. 2017;31(6):1014–1020.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Vilavella M, Garcia-Doval I, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatology Venereol. 2014;28(7):907–914.
   PubMed Web of Science ®Google Scholar
• Arnold T, Schaarschmidt M-L, Herr R, et al. Drug survival rates and reasons for drug discontinuation in psoriasis. J Dtsch Dermatol Ges. 2016;14(11):1089–1099.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148–1158.
   PubMed Web of Science ®Google Scholar
• Cao Z, Carter C, Wilson KL, et al. Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2015;26(2):113–120.
   PubMed Web of Science ®Google Scholar
• D’Souza LS, Payette MJ. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. J Am Acad Dermatol. 2015;72(4):589–598.
   PubMed Web of Science ®Google Scholar
• Foster SA, Zhu B, Guo J, et al. Patient characteristics, health care resource utilization, and costs associated with treatment-regimen failure with biologics in the treatment of psoriasis. J Manag Care Spec Pharm. 2016;22(4):396–405.
   PubMedGoogle Scholar
• Rubin DT, Mittal M, Davis M, et al. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. J Manag Care Spec Pharm. 2017;23(8):859–867.
   PubMedGoogle Scholar
• Ben-Horin S. Loss of response to anti-tumor necrosis factors: what is the next step? Dig Dis. 2014;32(4):384–388.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135.
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, et al. psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatology Symp Proc. 2004;9(2):136–139.
   PubMed Web of Science ®Google Scholar
• Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):729–736.
   PubMed Web of Science ®Google Scholar
• Oussedik E, Cardwell LA, Patel NU, et al. An anchoring-based intervention to increase patient willingness to use injectable medication in psoriasis. JAMA Dermatology. 2017 June;153:932.
   Web of Science ®Google Scholar
• Chen Z, Gong Y, Shi Y. Novel biologic agents targeting interleukin-23 and interleukin-17 for moderate-to-severe psoriasis. Clin Drug Investig. 2017;37(10):891–899.
   PubMed Web of Science ®Google Scholar
• Jeon C, Sekhon S, Yan D, et al. Monoclonal antibodies inhibiting IL-12, −23, and −17 for the treatment of psoriasis. Hum Vaccin Immunother. 2017;13:2247–2259.
   PubMed Web of Science ®Google Scholar